First Phase 3 Trial Evaluating Monotherapy with a Cardiac Myosin Inhibitor Compared to Monotherapy with a Beta Blocker in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy SOUTH SAN...
Enforcement Report - Week of February 1, 2023
Enforcement Report - Week of January 19, 2022
Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on rare diseases, today announced the initiation of a Phase 2b clinical trial of Tesomet in patients with Prader-Willi syndrome (PWS). Tesomet is an investigational fixed-dose combination therapy of tesofensine, a triple monoamine reuptake inhibitor, and metoprolol, a beta-1 selective blocker. Data from the trial are expected in the first half of 2023.
Today’s announcement comes as industry experts work to avoid an extended shortage of Heparin, the preferred anticoagulant for many hospitalized patients. Heparin is commonly prescribed for patients with significant blood clots in their lungs or clogged arteries, and patients receiving dialysis, or undergoing major orthopedic and cardiac surgery. It is prescribed to more than 10 million Americans every year.
CHARLOTTE, N.C.--(BUSINESS WIRE)--ProvideGx, LLC, a subsidiary of Premier Inc. (NASDAQ: PINC), a healthcare improvement company developing a more stable and reliable supply chain for generic drugs in short supply, is collaborating with Baxter Healthcare Corporation to make additional generic drugs available for purchase through Premier’s group purchasing organization.
Healthcare management company Premier has pledged to attack hospital drug shortages in the U.S. and has created a new subsidiary to focus exclusively on the problem. It says its first offering will be to market soon.
Enforcement Report - Week of November 21, 2018
Enforcement Report - Week of November 14, 2018
Saniona has gotten the go-ahead it needs to continue a midstage trial of its combination therapy for Prader-Willi syndrome (PWS), a debilitating genetic disorder that causes insatiable appetite and obesity.